Agenda: Risks, Dead-ends & Avoidable Delays: Optimising Preclinical Planning & Biomarker Targets to Maximise Clinical Development in Precision & Immuno-Oncology

10:00 am Welcome to the Labcorp Oncology Engager

  • Wolfgang Schlaeger Country Head, Director Clinical Operations, GCD Clinical Operations, Germany, Labcorp Oncology
  • Kenneth Morrison Vice President, Regional Oncology Growth, Labcorp Oncology

10:05 am Evolution or Revolution in Clinical Immuno-Oncology: What’s Next ?

  • Wolfgang Schlaeger Country Head, Director Clinical Operations, GCD Clinical Operations, Germany, Labcorp Oncology

Synopsis

• Hear about specific issues in cancer care in Germany, the reliance on radiation committees and the need to develop commercial strategies
• Learn how a surge in digital healthcare technology can be included in product development and evidence generation

10:20 am With the End in Mind – The Importance of an Integrated Preclinical & Clinical Approach

  • Bruce Hamilton Director of Biopharmaceutical Development, Labcorp Oncology

Synopsis

• The importance of clearly defined CDP in informing preclinical planning and execution in the Immuno-Oncology space
• Learn how to optimise Go / No-Go for Immuno-Oncology agents in the preclinical space
• Key lessons learned in de-risking through “end-in-mind” approach into the clinical space

10:40 am The Urgent Necessity of Innovating Clinical Trial Methodologies in Oncology

  • Ravi Karra Senior Medical Director, Global Clinical Development, Labcorp Oncology

Synopsis

• An overview of complex innovative trial designs
• Do innovative trial designs translate into reduces development timelines, and do they translate into greater access to oncology treatments?

11:00 am Q&A

  • Kenneth Morrison Vice President, Regional Oncology Growth, Labcorp Oncology
  • Wolfgang Schlaeger Country Head, Director Clinical Operations, GCD Clinical Operations, Germany, Labcorp Oncology
  • Ravi Karra Senior Medical Director, Global Clinical Development, Labcorp Oncology
  • Bruce Hamilton Director of Biopharmaceutical Development, Labcorp Oncology
  • Paul Baldrick Executive Director, Nonclinical Regulatory Strategy, Product Development and Market Access Consulting, Labcorp Oncology
  • Stephanie Grote-Wessels Senior Study Director, Immunotoxicology, Labcorp Oncology

Synopsis

You can take part in this interactive Q&A by submitting questions via the live chat tab

11:30 am End of the Labcorp Oncology Engager

Synopsis

We hope you enjoyed today’s online event.
If you have any follow-up questions after the event, please let us know by emailing info@hansonwade.com